Heritage Pharmaceuticals Inc. issued the following statement regarding its recent agreement with the United States Department of Justice, Antitrust Division (“DOJ”) that was announced on May 31, 2019:
EAST BRUNSWICK, N.J., June 11, 2019 /PRNewswire/ --Heritage Pharmaceuticals Inc. issued the following statement regarding its recent agreement with the United States Department of Justice, Antitrust Division (“DOJ”) that was announced on May 31, 2019: “Heritage Pharmaceuticals would like to clarify that the Company was not required to enter, and did not enter, a guilty plea as a part of the recent agreement with the DOJ. In addition, the separate settlement with the United States Department of Justice, Civil Division includes a determination by the Office of Inspector General of the Department of Health and Human Services (“OIG-HHS”) that Heritage will not be excluded from participating in the federal health care programs. Heritage looks forward to putting these issues behind us as we continue to focus on Heritage’s bright future in the generics industry.” About Heritage
SOURCE Heritage Pharmaceuticals Inc. |